Al­ny­lam's R&D up­date in­cludes 3 halts, Alzheimer's time­line and an­oth­er NASH

Al­ny­lam Phar­ma­ceu­ti­cals tout­ed its high prob­a­bil­i­ty of suc­cess in bring­ing as­sets from Phase I to Phase III — about 62% com­pared to an in­dus­try av­er­age of 5% to 10% — in an R&D up­date Thurs­day.

But, even the RNAi drug de­vel­op­er with five med­i­cines now un­der its wings will come out with the scis­sors and scrap stud­ies it finds lack­ing, as the Boston-area biotech out­lined in an in­vestor pre­sen­ta­tion. That in­cludes cem­disir­an for kid­ney dis­ease IgA nephropa­thy, an ear­ly-stage drug for gout and lumasir­an for re­cur­rent re­nal stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER